FDA Approves AstraZeneca's 'Truqap' and MSD's 'Welireg' Combination Therapies, Expanding Oncology Portfolio
FDA Streamlines Oncology Announcements and the Underlying Purpose
The U.S. Food and Drug Administration (FDA) has recently streamlined its approval notification policies in the oncology and hematological malignancies fields, focusing on real-time updates through the comprehensive database, Drugs@FDA, instead of individual press releases. This aims to efficiently process the increasing number of approvals for precision oncology drugs, bispecific antibodies, and immune checkpoint inhibitors, thereby resolving administrative bottlenecks. The industry believes that this policy goes beyond mere administrative convenience and aims to quickly and transparently deliver the latest label update information in the rapidly evolving cancer treatment market. As a result, the ability to actively monitor and extract data from the FDA database has become a new competitive advantage for pharmaceutical companies and investors.
Significance of AstraZeneca's Truqap Combination Therapy Approval for Prostate Cancer
On June 12, 2026, the FDA approved AstraZeneca's AKT inhibitor, Truqap (active ingredient: capivasertib), in combination with abiraterone and prednisone. This approval represents a significant milestone, targeting adult patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN loss. The Phase 3 CAPItello-281 study demonstrated that the median radiographic progression-free survival (rPFS) was increased from 25.7 months to 33.2 months compared to the control group, reducing the risk of disease progression by 19%. In 2026, the global prostate cancer market is estimated at $14 billion to $25.7 billion, and Truqap has secured a leading position as the first and only targeted treatment option for PTEN loss.
MSD's Welireg Expands Adjuvant Therapy for Renal Cell Carcinoma and Commercial Prospects
On the same day, the FDA approved MSD's Welireg (active ingredient: belzutifan) in combination with Keytruda (active ingredient: pembrolizumab) as adjuvant therapy for renal cell carcinoma (RCC). Welireg is a HIF-2Ξ± inhibitor, and the Phase 3 LITESPARK-022 study demonstrated that the combination therapy reduced the risk of recurrence or death by 28% compared to Keytruda monotherapy. The 2-year recurrence-free survival (DFS) rate was 80.7%, significantly higher than the 73.7% in the control group, indicating improved potential for cure in early-stage patients. This development is expected to accelerate the transition to a standard of care for the treatment of advanced renal cell carcinoma, a market worth over $7 billion annually, with the combination of immune checkpoint inhibitors and targeted therapies.
Proactive M&A and Licensing Deals Demonstrate the Benefits of VC Investment
These late-stage clinical successes and rapid regulatory approvals highlight the importance of proactive venture capital (VC) and big pharma investment strategies for identifying promising biotech companies. Welireg was acquired by MSD through the acquisition of Peloton Therapeutics in 2019 for a total of $2.2 billion ($1.05 billion upfront and $1.15 billion in milestones), and this expansion of indications directly leads to the achievement of commercial milestones. AstraZeneca's Truqap also grew into a blockbuster drug based on licensing agreements with Astex Therapeutics (approximately $5 million upfront and $270 million in milestones). These examples reaffirm that the evaluation of early-stage deals that combine promising target molecules and companion diagnostic technologies is a key driver of growth in the global pharmaceutical and biotechnology ecosystem.
The FDA's approval of 'Truqap' and 'Welireg' combination therapies will be a catalyst for maximizing the commercial value of molecular targeted therapies in the approximately $20 billion prostate cancer market and the $7 billion adjuvant therapy market for renal cell carcinoma. From an investor's perspective, as demonstrated by MSD's 2019 acquisition of Peloton for a total of $2.2 billion, the path to recouping investment is clearly demonstrated through early-stage pipeline licensing and mergers and acquisitions, followed by regulatory approval and expansion of indications, leading to the realization of commercial milestones. From a researcher's perspective, the data from the Phase 3 CAPItello-281 and LITESPARK-022 studies, including rPFS of 33.2 months and a 28% reduction in the risk of recurrence, will establish precision medicine design and companion diagnostic combination models for patients with specific gene deficiencies (e.g., PTEN) as a standard strategy for increasing the success rate of clinical trials. Industry stakeholders should respond to the regulatory changes, where the FDA omits individual press releases and updates labels in real-time through the Drugs@FDA database, by accurately predicting the point at which the market share of competing drugs such as 'Xtandi' and 'Zytiga' will decline and by establishing an automated information collection system to overcome long-term market asymmetry.
Source: FDA Drug Approvals (rss)